## **NOTICE**

## **ALTERNATIVE MEDICATION AUTHORIZATION**

An Act respecting prescription drug insurance (chapter A-29.01, s. 60.1)

I hereby authorize the temporary use of the following alternative medication:

| 99114073 | Amoxicillin/<br>Potassium<br>clavulanate | 1mL | 400 mg<br>57 mg/5 mL | Oral Susp. |  |  |  |
|----------|--|-----|----------------------|------------|--|--|--|
|----------|--|-----|----------------------|------------|--|--|--|

until the following medication, appearing on the *List of Medications* attached to the *Regulation respecting the List of medications covered by the basic prescription drug insurance plan*, is no longer out of stock:

| 02238830 | Clavulin-400 | GSK | 70 ml | 400 mg<br>57 mg/5 mL | Oral Susp. | 17.95 | 0.2564 |  |
|----------|--------------|-----|-------|----------------------|------------|-------|--------|--|
|----------|--------------|-----|-------|----------------------|------------|-------|--------|--|

This notice has effect retroactively from 5 October 2022.

Québec, 19 October 2022

Original signed by

MARCO THIBAULT
President and Chief Executive Officer
Régie de l'assurance maladie du Québec

Publication of this notice on the website of the Régie de l'assurance maladie du Québec imparts authentic value to it.